Privia Health Group Inc. (NASDAQ:PRVA) traded with a subtraction of -$3.0 to $34.01 on Thursday, a downside of -8.09 percent. An average of 1,173,757 shares of common stock have been traded in the last five days. There was a fall of -$8.02 in the past week, and it reached a new high 19 times over the past 12 months. The last 20 days have seen an average of 980,649 shares traded, while the 50-day average volume stands at 1,005,058.
PRVA stock has decreased by -11.84% in the last month. The company shares reached their 1-month lowest point of $33.96 on 09/22/22. With the stock rallying to its 52-week high on 08/24/22, shares of the company touched a low of $17.99 and a high of $44.64 in 52 weeks. It has reached a new high 26 times so far this year and achieved 43.06% or $8.13 in price. In spite of this, the price is down -23.80% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
2 days have passed since Privia Health Group Inc. (PRVA) last reported insider trading activity. Mehrotra Parth, who is President and COO, most recently acquired $63,705 shares at $37.31 per share on Sep 20. In this transaction, the insider spent $2,376,834. President and COO, Mehrotra Parth, disposed of 66,011 shares at a price of $37.30 on Sep 20. The insider now owns more than $2,462,210 worth of shares. Prior to that, President and COO Mehrotra Parth went on to Sale 107,702 shares at $37.82 each on Sep 19. An amount of $4,072,758 was transacted.
Privia Health Group Inc. (PRVA) has a trailing price-to-sales (P/S) ratio at 3.69, the price-to-book (PB) ratio at 9.03, and the price-to-cash flow ratio at 83.81.
The quick ratio of Privia Health Group Inc. for the three months ended June 29 was 2.00, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $63.66 million compared to revenue of $966.22 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Privia Health Group Inc.’s return on assets was -7.00%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$10.48 million in the quarter, while revenues of -$17.51 million were shrunk -1546.28%. The analyst consensus anticipated Privia Health Group Inc.’s latest quarter earnings to come in at -$0.03 per share, but it turned out to be -$0.1, a -233.30% surprise. For the quarter, EBITDA amounted to -$3.44 million. Shareholders own equity worth $111.33 million.
From a technical analysis perspective, let’s take a brief look at Privia Health Group Inc. (PRVA) price momentum. RSI 9-day as of the close on 21 September was 27.66%, suggesting the stock is oversold, with historical volatility in this time frame at 54.55%.
As of today, PRVA’s price is $37.17 -19.09% or -$8.02 from its 5-day moving average. PRVA is currently trading -20.88% lower than its 20-day SMA and +54.62% higher than its 100-day SMA. However, the stock’s current price level is +4.01% above the SMA50 and +57.55% above the SMA200.
The stochastic %K and %D were 4.03% and 10.78%, respectively, and the average true range (ATR) was 2.29. With the 14-day stochastic at 0.40% and the average true range at 2.28, the RSI (14) stands at 35.93%. The stock has reached -3.23 on the 9-day MACD Oscillator while the 14-day reading was at -3.66.
The consensus rating for Privia Health Group Inc. (PRVA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PRVA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 13 others rate it as a “buy”.
What is PRVA’s price target for the next 12 months?
Analysts predict a range of price targets between $35.00 and $58.00, with a median target of $45.50. Taking a look at these predictions, the average price target given by analysts for Privia Health Group Inc. (PRVA) stock is $46.83.